These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 17515296)

  • 21. Effect of first-trimester nuchal translucency on second-trimester maternal serum biochemical screening for Down's syndrome.
    Thilaganathan B; Slack A; Wathen NC
    Ultrasound Obstet Gynecol; 1997 Oct; 10(4):261-4. PubMed ID: 9383877
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Spencer K; Souter V; Tul N; Snijders R; Nicolaides KH
    Ultrasound Obstet Gynecol; 1999 Apr; 13(4):231-7. PubMed ID: 10341399
    [TBL] [Abstract][Full Text] [Related]  

  • 23. First-trimester screening for Down syndrome with ductus venosus Doppler studies in addition to nuchal translucency and serum markers.
    Borrell A; Gonce A; Martinez JM; Borobio V; Fortuny A; Coll O; Cuckle H
    Prenat Diagn; 2005 Oct; 25(10):901-5. PubMed ID: 16034840
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Screening for trisomy 21 by fetal nuchal translucency and maternal age: a multicenter project in Germany, Austria and Switzerland.
    Gasiorek-Wiens A; Tercanli S; Kozlowski P; Kossakiewicz A; Minderer S; Meyberg H; Kamin G; Germer U; Bielicki M; Hackelöer BJ; Sarlay D; Kuhn P; Klapp J; Bahlmann F; Pruggmayer M; Schneider KT; Seefried W; Fritzer E; von Kaisenberg CS;
    Ultrasound Obstet Gynecol; 2001 Dec; 18(6):645-8. PubMed ID: 11844207
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fetal right ventricular contraction and relaxation times at 11-13 weeks' gestation on speckle tracking imaging.
    Persico N; Fabietti I; Baffero GM; Fedele L; Nicolaides KH
    Ultrasound Obstet Gynecol; 2014 Mar; 43(3):284-90. PubMed ID: 23939754
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Screening for Down's syndrome by fetal nuchal translucency measurement in a general obstetric population.
    Pajkrt E; van Lith JM; Mol BW; Bleker OP; Bilardo CM
    Ultrasound Obstet Gynecol; 1998 Sep; 12(3):163-9. PubMed ID: 9793187
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Screening for aneuploidies by maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-13+6 gestational weeks.
    Karadzov-Orlić N; Egić A; Filimonović D; Marinković M; Damnjanović-Pazin B; Milovanović Z; Joksić I; Branković S; Lukić R; Mandić V; Cerović N; Mojović D; Plamenac S; Stanković M; Maglić D; Mikovć Z
    Srp Arh Celok Lek; 2012; 140(9-10):606-11. PubMed ID: 23289277
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Screening for fetal trisomy 21 in the first trimester of pregnancy: maternal serum free beta-hCG and fetal nuchal translucency thickness.
    Noble PL; Abraha HD; Snijders RJ; Sherwood R; Nicolaides KH
    Ultrasound Obstet Gynecol; 1995 Dec; 6(6):390-5. PubMed ID: 8903913
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nuchal translucency and nasal bone for trisomy 21 screening: single center experience.
    Monni G; Zoppi MA; Ibba RM; Floris M; Manca F; Axiana C
    Croat Med J; 2005 Oct; 46(5):786-91. PubMed ID: 16158472
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Integrated ultrasound and biochemical screening for trisomy 21 using fetal nuchal translucency, absent fetal nasal bone, free beta-hCG and PAPP-A at 11 to 14 weeks.
    Cicero S; Bindra R; Rembouskos G; Spencer K; Nicolaides KH
    Prenat Diagn; 2003 Apr; 23(4):306-10. PubMed ID: 12673635
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Additional first-trimester ultrasound markers.
    Sonek J; Nicolaides K
    Clin Lab Med; 2010 Sep; 30(3):573-92. PubMed ID: 20638573
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Screening for trisomy 21 by maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-14 weeks: a German multicenter study.
    von Kaisenberg CS; Gasiorek-Wiens A; Bielicki M; Bahlmann F; Meyberg H; Kossakiewicz A; Pruggmayer M; Kamin G; Fritzer E; Harris C; Arnold N;
    J Matern Fetal Neonatal Med; 2002 Aug; 12(2):89-94. PubMed ID: 12420837
    [TBL] [Abstract][Full Text] [Related]  

  • 33. First-trimester contingent screening for trisomies 21, 18 and 13 by fetal nuchal translucency and ductus venosus flow and maternal blood cell-free DNA testing.
    Kagan KO; Wright D; Nicolaides KH
    Ultrasound Obstet Gynecol; 2015 Jan; 45(1):42-7. PubMed ID: 25307357
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Screening for Down syndrome using first-trimester ultrasound and second-trimester maternal serum markers in a low-risk population: a prospective longitudinal study.
    Audibert F; Dommergues M; Benattar C; Taieb J; Thalabard JC; Frydman R
    Ultrasound Obstet Gynecol; 2001 Jul; 18(1):26-31. PubMed ID: 11489221
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Screening for trisomy 21 with maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-14 weeks: a regional experience from Germany.
    Soergel P; Pruggmayer M; Schwerdtfeger R; Muhlhaus K; Scharf A
    Fetal Diagn Ther; 2006; 21(3):264-8. PubMed ID: 16601335
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Likelihood ratio for trisomy 21 in fetuses with tricuspid regurgitation at the 11 to 13 + 6-week scan.
    Faiola S; Tsoi E; Huggon IC; Allan LD; Nicolaides KH
    Ultrasound Obstet Gynecol; 2005 Jul; 26(1):22-7. PubMed ID: 15937972
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of nuchal translucency measurement on second-trimester biochemical screening for Down's syndrome.
    Kadir RA; Economides DL
    Ultrasound Obstet Gynecol; 1997 Apr; 9(4):244-7. PubMed ID: 9168574
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined measurement of fetal nuchal translucency, maternal serum free beta-hCG, and pregnancy-associated plasma protein A for first-trimester Down's syndrome screening.
    Tsai MS; Huang YY; Hwa KY; Cheng CC; Lee FK
    J Formos Med Assoc; 2001 May; 100(5):319-25. PubMed ID: 11432311
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Additional performance of nasal bone in first trimester screening.
    Kozlowski P; Knippel AJ; Froehlich S; Stressig R
    Ultraschall Med; 2006 Aug; 27(4):336-9. PubMed ID: 16596511
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intrauterine lethality of trisomy 21 fetuses with increased nuchal translucency thickness.
    Hyett JA; Sebire NJ; Snijders RJ; Nicolaides KH
    Ultrasound Obstet Gynecol; 1996 Feb; 7(2):101-3. PubMed ID: 8776233
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.